Search Results - "Delmar, P"

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer by Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J

“…Background: Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer…”
Get full text

Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease by Lansdall, Claire J., McDougall, F., Butler, L. M., Delmar, P., Pross, N., Qin, S., McLeod, L., Zhou, X., Kerchner, G. A., Doody, R. S.

“…Background Consensus is lacking on what constitutes a meaningful score change for individual patients on clinical outcome assessments (COAs) that are commonly…”
Get full text

Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab by Klein, Gregory, Delmar, P., Kerchner, G. A., Hofmann, C., Abi-Saab, D., Davis, A., Voyle, N., Baudler, M., Fontoura, P., Doody, R.

“…Previous findings from the positron emission tomography (PET) substudy of the SCarlet RoAD and Marguerite RoAD open-label extension (OLE) showed gantenerumab…”
Get full text

Psychometric Properties of the Clinical Dementia Rating — Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer’s Disease Population by McDougall, Fiona, Edgar, C., Mertes, M., Delmar, P., Fontoura, P., Abi-Saab, D., Lansdall, C. J., Boada, M., Doody, R.

“…Background The Clinical Dementia Rating-Sum of Boxes (CDR-SB) has been proposed as a primary outcome for use in prodromal AD trials. However, the psychometric…”
Get full text

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma by Temam, S., Spicer, J., Farzaneh, F., Soria, J.C., Oppenheim, D., McGurk, M., Hollebecque, A., Sarini, J., Hussain, K., Soehrman Brossard, S., Manenti, L., Evers, S., Delmar, P., Di Scala, L., Mancao, C., Feuerhake, F., Andries, L., Ott, M.G., Passioukov, A., Delord, J.P.

“…In addition to inhibiting epidermal growth factor receptor (EGFR) signaling, anti-EGFR antibodies of the IgG1 ‘subtype’ can induce a complementary therapeutic…”
Get full text

Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis by Hourcade-Potelleret, F, Laporte, S, Lehnert, V, Delmar, P, Benghozi, Renée, Torriani, U, Koch, R, Mismetti, P

“…Epidemiological evidence that the risk of coronary heart disease is inversely associated with the level of high-density lipoprotein cholesterol (HDL-C) has…”
Get more information

VarMixt: efficient variance modelling for the differential analysis of replicated gene expression data by Delmar, Paul, Robin, Stéphane, Daudin, Jean Jacques

“…Motivation: Identifying differentially regulated genes in experiments comparing two experimental conditions is often a key step in the microarray data analysis…”
Get full text

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer by Tan, E.-H., Ramlau, R., Pluzanska, A., Kuo, H.-P., Reck, M., Milanowski, J., Au, J. S.-K., Felip, E., Yang, P.-C., Damyanov, D., Orlov, S., Akimov, M., Delmar, P., Essioux, L., Hillenbach, C., Klughammer, B., McLoughlin, P., Baselga, J.

“…Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient…”
Get full text

803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) by Van Cutsem, E, Jayson, G, Dive, C, Dilba, P, de Haas, S, Wild, N, Delmar, P, Scherer, S.J

Get full text

9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC) by Mok, T, Gorbunova, V, Juhasz, E, Szima, B, Burdaeva, O, Yu, C.J, Delmar, P, Pallaud, C, Jonnaert, M, Reck, M

Get full text

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab by Jayson, G.C, de Haas, S, Delmar, P, Miles, D.W, Shah, M.A, Van Cutsem, E, Carmeliet, P, Hegde, P, Wild, N, Scherer, S.J

Get full text

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab by Lambrechts, D, Delmar, P, Miles, D.W, Leighl, N, Saltz, L, Escudier, B, Van Cutsem, E, Scherer, S.J, Carmeliet, P, de Haas, S

Get full text

1415 POSTER Blood Plasma VEGFA Analysis in the AVAGAST Randomized Study of First-line Bevacizumab (bev) + Capecitabine/Cisplatin (cape/cis) in Patients (pts) With Advanced Gastric Cancer (AGC) by Shah, M.A, Kang, Y, Ohtsu, A, Roman, L, Nunes, J, Li, C, Delmar, P, Langer, B, Scherer, S.J, Van Cutsem, E

Get full text

Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease by Bateman, Randall J., Smith, Janice, Donohue, Michael C., Delmar, Paul, Abbas, Rachid, Salloway, Stephen, Wojtowicz, Jakub, Blennow, Kaj, Bittner, Tobias, Black, Sandra E., Klein, Gregory, Boada, Mercè, Grimmer, Timo, Tamaoka, Akira, Perry, Richard J., Turner, R. Scott, Watson, David, Woodward, Michael, Thanasopoulou, Angeliki, Lane, Christopher, Baudler, Monika, Fox, Nick C., Cummings, Jeffrey L., Fontoura, Paulo, Doody, Rachelle S.

“…In two randomized trials, the use of gantenerumab (an anti-Aβ monoclonal antibody) did not lead to slower clinical decline than placebo over 116 weeks among…”
Get full text

Mixture model on the variance for the differential analysis of gene expression data by Delmar, Paul, Robin, Stéphane, Tronik-Le Roux, Diana, Daudin, Jean Jacques

“…In microarray experiments, accurate estimation of the gene variance is a key step in the identification of differentially expressed genes. Variance models go…”
Get full text

9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations by Soulières, D, Ciuleanu, T, Stelmakh, L, Whittom, R, Delmar, P, Rohr, K, Brugger, W, Cappuzzo, F

Get full text

9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC) by Leighl, N, Reck, M, de Haas, S, Evers, S, Delmar, P, Manegold, C, Scherer, S

Get full text

16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer by Lambrechts, D, Delmar, P, Buysschaert, I, Claes, B, Yesilyurt, B.T, Verslype, C, Foernzler, D, Carmeliet, P, Scherer, S, Van Cutsem, E

Get full text

P33 Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab by Klein, G., Duning, T., Delmar, P., Kerchner, G.A., Hofmann, C., Abi-Saab, D., Ristic, S., Davis, A., Voyle, N., Baudler, M., Fontoura, P., Doody, R.

Get full text

Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib by Davies, J., Martinec, M., Martina, R., Delmar, P., Coudert, M., Bordogna, W., Golding, S., Crane, G.

Get full text